文献速递淋巴瘤

维布妥昔单抗联合方案治疗复发弥漫性大B细胞淋巴瘤

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2025-01-07

ECHELON-3是一项随机双盲安慰剂对照多中心3期试验,比较维布妥昔单抗(BV)联合来那度胺(Len)和利妥昔单抗(R)与安慰剂联合Len和R在复发或难治性弥漫性大B细胞淋巴瘤(DLBCL)患者中的疗效与安全性。结果显示BV+Len+R组中位总生存期13.8个月,优于安慰剂组的8.5个月(HR 0.63,95%CI 0.45-0.89,P=0.009),中位无进展生存期4.2个月对2.6个月(HR 0.53,95%CI 0.38-0.73,P<0.001),客观缓解率64%对42%(P<0.001)。

要点

  • BV+Len+R较安慰剂+Len+R显著改善复发或难治性DLBCL患者的总生存期(中位13.8个月对8.5个月,HR 0.63)。
  • BV+Len+R组中位无进展生存期4.2个月,安慰剂+Len+R组2.6个月(HR 0.53,P<0.001)。
  • 两组治疗期间不良事件发生率均为97%,最常见为中性粒细胞减少、血小板减少、腹泻和贫血。

核心结论

  • 在重度经治的复发或难治性DLBCL患者中,BV+Len+R显示出统计学显著的生存获益,且安全性可控。

研究设计与样本

  • ECHELON-3是一项随机、双盲、安慰剂对照、多中心、3期试验。
  • 共纳入230例复发或难治性DLBCL患者,随机分配至BV+Len+R组(n=112)或安慰剂+Len+R组(n=118)。
  • 给药方案为BV或安慰剂每3周一次,Len每日一次,R每3周一次。
  • 主要终点为总生存期(OS),次要终点包括研究者评估的无进展生存期(PFS)和客观缓解率(ORR)。
  • 在发生134例OS事件后进行预设期中分析,双侧P=0.0232为疗效边界。

主要发现

  • 中位随访16.4个月,BV+Len+R组中位OS为13.8个月,安慰剂+Len+R组为8.5个月(HR 0.63,95%CI 0.45-0.89;双侧P=0.009)。
  • BV+Len+R组中位PFS为4.2个月,安慰剂+Len+R组为2.6个月(HR 0.53,95%CI 0.38-0.73;双侧P<0.001)。
  • BV+Len+R组ORR为64%(95%CI 55-73),安慰剂+Len+R组为42%(95%CI 33-51)(双侧P<0.001)。
  • BV+Len+R组完全缓解率为40%,安慰剂+Len+R组为19%。
  • 两组治疗期间不良事件发生率均为97%,两组最常见不良事件均为中性粒细胞减少、血小板减少、腹泻和贫血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL. METHODS: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL. Patients received BV or placebo once every 3 weeks, Len once daily, and R once every 3 weeks. The primary end point was overall survival (OS), and secondary end points included investigator-assessed progression-free survival (PFS) and objective response rate (ORR). A prespecified interim analysis was performed after 134 OS events, with two-sided P = .0232 as the efficacy boundary. RESULTS: Patients (N = 230) were randomly assigned to receive BV + Len + R (n = 112) or placebo + Len + R (n = 118). Two patients in the placebo arm did not receive treatment. With a median follow-up of 16.4 months, the median OS was 13.8 months with BV + Len + R versus 8.5 months with placebo + Len + R (hazard ratio, 0.63 [95% CI, 0.45 to 0.89]; two-sided P = .009). The median PFS was 4.2 months with BV + Len + R versus 2.6 months with placebo + Len + R (hazard ratio, 0.53 [95% CI, 0.38 to 0.73]; two-sided P < .001). The ORR was 64% ([95% CI, 55 to 73]; two-sided P < .001) with BV + Len + R and 42% (95% CI, 33 to 51) with placebo + Len + R; complete response rates were 40% and 19%, respectively. Treatment-emergent adverse events (AEs) occurred in 97% of patients in both arms. In both arms, the most common treatment-emergent AEs were neutropenia, thrombocytopenia, diarrhea, and anemia. CONCLUSION: BV + Len + R demonstrated a statistically significant survival benefit with a manageable safety profile in heavily pretreated patients with R/R DLBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bartlett NL, Hahn U, Kim WS, et al. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025. PMID: 39772655. doi:10.1200/JCO-24-02242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。